Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
ARUP Laboratories, |
RCV001811149 | SCV002047750 | likely benign | not provided | 2021-04-28 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV004526596 | SCV005039657 | uncertain significance | not specified | 2024-03-20 | criteria provided, single submitter | clinical testing | Variant summary: HBB c.60C>A (p.Asn20Lys, also known as Hb D Ouled Rabah) results in a non-conservative amino acid change located in the Globin domain (IPR000971) of the encoded protein sequence. Four of five in-silico tools predict a benign effect of the variant on protein function. The variant was absent in 251238 control chromosomes in gnomAD v2. The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. c.60C>A has been reported in the literature along with a VUS missense p.Glu23Gln in individuals affected with Beta Thalassemia (example, Elion_1973). These report(s) do not provide unequivocal conclusions about association of the variant with Beta Thalassemia. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Additionally, p.Asn20Ser has been evaluated associated with disease as a splice-site variant, however such indirect evidence cannot be used for c.60C>A, as consensus agreement among computation tools predict no significant impact on normal splicing of this variant. The following publication have been ascertained in the context of this evaluation (PMID: 4719147). ClinVar contains an entry for this variant (Variation ID: 15153). Based on the evidence outlined above, the variant was classified as uncertain significance. |
OMIM | RCV000016321 | SCV000036589 | other | HEMOGLOBIN D (OULED RABAH) | 2017-12-12 | no assertion criteria provided | literature only |